158 related articles for article (PubMed ID: 36080216)
21. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation Weakens but Does Not Inhibit Membrane Binding and Clustering of K-Ras4B.
Zhang SY; Sperlich B; Li FY; Al-Ayoubi S; Chen HX; Zhao YF; Li YM; Weise K; Winter R; Chen YX
ACS Chem Biol; 2017 Jun; 12(6):1703-1710. PubMed ID: 28448716
[TBL] [Abstract][Full Text] [Related]
23. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.
Tu Z; Gui L; Wang J; Li X; Sun P; Wei L
Gynecol Oncol; 2006 May; 101(2):274-9. PubMed ID: 16303170
[TBL] [Abstract][Full Text] [Related]
24. The higher level of complexity of K-Ras4B activation at the membrane.
Jang H; Banerjee A; Chavan TS; Lu S; Zhang J; Gaponenko V; Nussinov R
FASEB J; 2016 Apr; 30(4):1643-55. PubMed ID: 26718888
[TBL] [Abstract][Full Text] [Related]
25. Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation.
Zhang H; Ni D; Fan J; Li M; Zhang J; Hua C; Nussinov R; Lu S
J Chem Inf Model; 2022 Sep; 62(17):4222-4231. PubMed ID: 35994329
[TBL] [Abstract][Full Text] [Related]
26. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
27. [Regulation of [12Asp]K-ras4B on transcriptional activity of estrogen receptor in endometrial carcinoma HEC-1A cell lines].
Gui LM; Wei LH; Xu MX; Wang JL; Zhong YC; Li XP; Tu Z; Sun PM; Ma DL
Zhonghua Fu Chan Ke Za Zhi; 2004 Jan; 39(1):30-4. PubMed ID: 14989985
[TBL] [Abstract][Full Text] [Related]
28. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
29. Expression, purification, and characterization of soluble K-Ras4B for structural analysis.
Abraham SJ; Muhamed I; Nolet R; Yeung F; Gaponenko V
Protein Expr Purif; 2010 Oct; 73(2):125-31. PubMed ID: 20566322
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site.
Fang Z; Marshall CB; Nishikawa T; Gossert AD; Jansen JM; Jahnke W; Ikura M
Cell Chem Biol; 2018 Nov; 25(11):1327-1336.e4. PubMed ID: 30122370
[TBL] [Abstract][Full Text] [Related]
31. Computational Design of Myristoylated Cell-Penetrating Peptides Targeting Oncogenic K-Ras.G12D at the Effector-Binding Membrane Interface.
Li Z; Buck M
J Chem Inf Model; 2020 Jan; 60(1):306-315. PubMed ID: 31855604
[TBL] [Abstract][Full Text] [Related]
32. Membrane Composition and Raf[CRD]-Membrane Attachment Are Driving Forces for K-Ras4B Dimer Stability.
Andreadelis I; Kiriakidi S; Lamprakis C; Theodoropoulou A; Doerr S; Chatzigoulas A; Manchester J; Velez-Vega C; Duca JS; Cournia Z
J Phys Chem B; 2022 Feb; 126(7):1504-1519. PubMed ID: 35142524
[TBL] [Abstract][Full Text] [Related]
33. Dissociation of the K-Ras4B/PDEδ complex upon contact with lipid membranes: membrane delivery instead of extraction.
Weise K; Kapoor S; Werkmüller A; Möbitz S; Zimmermann G; Triola G; Waldmann H; Winter R
J Am Chem Soc; 2012 Jul; 134(28):11503-10. PubMed ID: 22721555
[TBL] [Abstract][Full Text] [Related]
34. Regulation of K-Ras4B Membrane Binding by Calmodulin.
Sperlich B; Kapoor S; Waldmann H; Winter R; Weise K
Biophys J; 2016 Jul; 111(1):113-22. PubMed ID: 27410739
[TBL] [Abstract][Full Text] [Related]
35. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
[TBL] [Abstract][Full Text] [Related]
36. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
37. A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2.
Martín-Gago P; Fansa EK; Klein CH; Murarka S; Janning P; Schürmann M; Metz M; Ismail S; Schultz-Fademrecht C; Baumann M; Bastiaens PI; Wittinghofer A; Waldmann H
Angew Chem Int Ed Engl; 2017 Feb; 56(9):2423-2428. PubMed ID: 28106325
[TBL] [Abstract][Full Text] [Related]
38. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
Lerner EC; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
[TBL] [Abstract][Full Text] [Related]
39. Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect.
He X; Du K; Wang Y; Fan J; Li M; Ni D; Lu S; Bian X; Liu Y
Front Mol Biosci; 2022; 9():860962. PubMed ID: 35463958
[TBL] [Abstract][Full Text] [Related]
40. Probing Colocalization of N-Ras and K-Ras4B Lipoproteins in Model Biomembranes.
Li L; Dwivedi M; Patra S; Erwin N; Möbitz S; Winter R
Chembiochem; 2019 May; 20(9):1190-1195. PubMed ID: 30604476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
